A Phase 2 interventional study of RVT-1401 and Placebo in Myasthenia Gravis, sponsored by Immunovant Sciences GmbH. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-20.
Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.
Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 82nd largest by enrollment of the 108 interventional ones that give a count, is one of 14 that started in 2019, is one of 26 in phase 2, and was the 41st registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
George Washington University · Sites in United States
Ages 18+
Amgen · Sites in United States, Argentina, Brazil and 5 more countries
Ages 2–17
argenx · Sites in United States, Belgium, Greece and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 38 · Phase 3 51 · Phase 4 3
First in 1995; this study’s year is marked. 14 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 56 across the 108 interventional studies, 226 across the 36 observational. Of the 64 that completed or were terminated, 41 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
96 of 144 have an industry lead sponsor. The 10 most frequent:
Immunovant Sciences GmbH is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 5 (45%) have results posted.
Immunovant Sciences GmbH has 3 studies filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
18 of the studies in Myasthenia Gravis with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT06799247Phase 3Cartesian TherapeuticsInvestigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | 2026-12-30 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT06456580Phase 3Vor BiopharmaA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | 2027-03 |
| NCT06517758Phase 3Novartis PharmaceuticalsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | 2027-04-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 144 studies in Myasthenia Gravis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Other, more specific inclusion criteria are defined in the protocol.
Exclusion Criteria:
Other, more specific exclusion criteria are defined in the protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RVT-1401 680 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
Drug: RVT-1401
RVT-1401 340 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
Drug: RVT-1401
Placebo for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
Drug: RVT-1401 · Drug: Placebo
Subcutaneous administration of RVT-1401
Subcutaneous administration of Placebo
Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.
Time frame: Up to Week 18
Open-Label Extension Period: Number of Participants Reporting AEs and SAEs
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as those AEs that started or worsened in severity after the initiation of study drug administration. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.
Time frame: Up to Week 18
Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Vital Signs
Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate and temperature were measured after resting for at least 5 minutes in a semi-supine position.
Time frame: Up to Week 7
Open-label Extension Period: Number of Participants With Clinically Significant Changes in Vital Signs
Vital signs including SBP, DBP, pulse rate and temperature were measured after resting for at least 5 minutes in a semi-supine position.
Time frame: Up to Week 18
Double-blind Treatment Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
Clinical laboratory parameters included clinical chemistry, hematology and urinalysis.
Time frame: Up to Week 7
Open-label Extension Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
Clinical laboratory parameters included clinical chemistry, hematology and urinalysis.
Time frame: Up to Week 18
Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)
Twelve-lead ECG was performed after 5 minutes of rest in the supine position.
Time frame: Up to Week 7
Open-label Extension Period: Number of Participants With Clinically Significant Changes in ECG
Twelve-lead ECG was performed after 5 minutes of rest in the supine position.
Time frame: Up to Week 18
Double-blind Treatment Period: Percent Change From Baseline in Levels of Total Immunoglobulin G (IgG)
Serum samples were collected for the analysis of total immunoglobulin G. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.
Time frame: Baseline (Day 1) and Up to Week 7
Double-blind Treatment Period: Percent Change From Baseline in IgG Subclasses 1, 2, 3 and 4
Serum samples were collected for the analysis of IgG 1, 2, 3 and 4 levels. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.
Time frame: Baseline (Day 1) and Up to Week 7
Double-Blind Treatment Period: Percent Change From Baseline in Anti-acetylcholine Receptor Immunoglobulin G (Anti-AChR-IgG) at Week 7
Serum samples were collected for the analysis of Anti-AChR-IgG. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.
Time frame: Baseline (Day 1) and Week 7
Double-Blind Treatment Period: Area Under the Concentration-time Curve From Time 0 to 168 Hours (AUC0-168h) of RVT-1401
Blood samples were collected for the analysis of Pharmacokinetic parameter AUC (0-168h).
Time frame: Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8
Open-label Extension Period: AUC0-168h of RVT-1401
Pharmacokinetic parameters were not estimated because the sparse PK sampling schedule did not allow for accurate estimates of these parameters.
Time frame: Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8, Week 9, Week 12 and Week 14
Double-Blind Treatment Period: Maximum Concentration (Cmax) of RVT-1401
Blood samples were collected for the analysis of Pharmacokinetic parameter Cmax.
Time frame: Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8
Open-label Extension Period: Cmax of RVT-1401
Blood samples were collected for the analysis of Pharmacokinetic parameter Cmax.
Time frame: Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8, Week 9, Week 12 and Week 14
Double-Blind Treatment Period: Trough Concentrations (Ctrough) of RVT-1401
Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic RVT-1401.
Time frame: Pre-dose
Open-label Extension Period: Ctrough of RVT-1401
Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic RVT-1401.
Time frame: Pre-dose
Double-blind Treatment Period: Change From Baseline in the Quantitative Myasthenia Gravis Score (QMG) Score
The QMG score is a physician-reported outcome measure was used to assess MG disease severity and pattern of deficits based on quantitative testing of affected muscle groups. The scale comprised of 13 test items that were graded on a scale of 0 (no myasthenic findings) to 3 (maximal myasthenic deficits). The total sum across all 13 items represents the QMG score. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1) and at Week 2, Week 3, Week 4, Week 5, Week 6 (Day 36) and Week 7
Double-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the QMG Score From Baseline
The response is defined as improvement from Baseline on the QMG score by =\> 3 points. The QMG score is a physician-reported outcome measure was used to assess MG disease severity and pattern of deficits based on quantitative testing of affected muscle groups. The scale comprised of 13 test items that were graded on a scale of 0 (no myasthenic findings) to 3 (maximal myasthenic deficits). The total sum across all 13 items represents the QMG score. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1) to Week 7
Double-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) Score
The MG-ADL is an 8-item, participant-reported outcome measure that assessed Myasthenia Gravis symptoms and their effects on activities of daily living, with each response graded from 0 (normal) to 3 (most severe). The MG-ADL score was calculated by totaling the rating for each of the 8 items. Total MG-ADL scores range from 0 to 24 with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1) and at Week 2, Week 3, Week 4, Week 5, Week 6 (Day 36), Week 7
Double-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the MG-ADL Score
The response was defined as improvement (decrease) from Baseline on the MG-ADL score by =\> 2 points. The MG-ADL is an 8-item, participant-reported outcome measure that assessed Myasthenia Gravis symptoms and their effects on activities of daily living, with each response graded from 0 (normal) to 3 (most severe). The MG-ADL score was calculated by totaling the rating for each of the 8 items. Total MG-ADL scores range from 0 to 24 with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug.
Time frame: Baseline (Day 1) to Week 7
Double-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Composite Score (MGC) Score
The MGC was developed by selecting the best performing items from 3 commonly used Myasthenia Gravis specific scales (QMG, Myasthenia Gravis manual muscle test, and MG-ADL) and is comprised of 10 functional domains: 3 ocular, 3 bulbar, 1 respiratory, 1 neck, and 2 limb items. The total score ranges from 0 (no myasthenic findings) to 50 (maximal myasthenic deficits). The scale measures symptoms and signs of MG in these domains incorporating both physician and participant-reported test items. Higher scores correlate with clinical worsening of the disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1) and at Week 2, Week 3, Week 4, Week 5, Week 6 (Day 36), Week 7
Double-Blind Treatment Period: Percentage of Participants With an Improvement on the MGC Score
The response was defined as improvement (decrease) from Baseline on the MGC score by =\> 3 points. The MGC was developed by selecting the best performing items from 3 commonly used Myasthenia Gravis specific scales (QMG, Myasthenia Gravis manual muscle test, and MG-ADL) and is comprised of 10 functional domains: 3 ocular, 3 bulbar, 1 respiratory, 1 neck, and 2 limb items. The total score ranges from 0 (no myasthenic findings) to 50 (maximal myasthenic deficits). The scale measures symptoms and signs of MG in these domains incorporating both physician and participant-reported test items. Higher scores correlate with clinical worsening of the disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug.
Time frame: Baseline (Day 1) to Week 7
Double-Blind Treatment Period: Change From Baseline in the Myasthenia Gravis Quality of Life 15 Revised Score (MG-QOL 15r) Score
The MG-QOL15r is a participant-reported questionnaire designed to assess how a participant's Myasthenia Gravis affects different aspects related to their quality of life. The scale includes 15 items that are graded on a scale of 0 to2; the total across is the sum of all 15 items and represents the MG-QOL15r score. The range of the MG-QOL15r score is 0 - 30. Higher scores indicate worse outcomes. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1) and at Week 4 and Week 7
Double-Blind Treatment Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies
The serum levels of anti-RVT-1401 antibodies were determined. All samples that were potentially positive were analyzed with the confirmation assay where presence of anti-RVT-1401 was confirmed; the therapeutic antibody was used to compete with the analytical responses of anti-drug antibody (ADA) to assess specificity of screened positive samples.
Time frame: Up to Week 7
Open-Label Extension Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies
The serum levels of anti-RVT-1401 antibodies were determined. All samples that were potentially positive were analyzed with the confirmation assay where presence of anti-RVT-1401 was confirmed; the therapeutic antibody was used to compete with the analytical responses of ADA to assess specificity of screened positive samples.
Time frame: Up to Week 18
This was a Phase 2a, randomized, double-blind (DB), placebo-controlled study with an Open-Label Extension (OLE) that was designed to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RVT-1401 versus placebo in acetylcholine receptor (AChR) antibody positive myasthenia gravis (MG) participants.
| Milestone | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week | Open-label Extension Period: RVT-1401 340 mg Biweekly |
|---|---|---|---|---|
| Started | 6 | 5 | 6 | 0 |
| Completed | 6 | 5 | 5 | 0 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Milestone | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week | Open-label Extension Period: RVT-1401 340 mg Biweekly |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 15 |
| Completed | 0 | 0 | 0 | 9 |
| Not completed | 0 | 0 | 0 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 3 |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.
| Participants | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Any AE | 5 | 4 | 5 |
| Any SAE | 0 | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as those AEs that started or worsened in severity after the initiation of study drug administration. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.
| Participants | Open-Label Extension Period: RVT-1401 340 mg Biweekly |
|---|---|
| Any AE | 10 |
| Any SAE | 1 |
Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate and temperature were measured after resting for at least 5 minutes in a semi-supine position.
| Participants | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Vital Signs | 0 | 0 | 0 |
Vital signs including SBP, DBP, pulse rate and temperature were measured after resting for at least 5 minutes in a semi-supine position.
| Participants | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Open-label Extension Period: Number of Participants With Clinically Significant Changes in Vital Signs | 0 | 0 | 0 |
Clinical laboratory parameters included clinical chemistry, hematology and urinalysis.
| Participants | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Double-blind Treatment Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters | 0 | 0 | 0 |
Clinical laboratory parameters included clinical chemistry, hematology and urinalysis.
| Participants | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Open-label Extension Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters | 0 | 0 | 0 |
Twelve-lead ECG was performed after 5 minutes of rest in the supine position.
| Participants | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) | 0 | 0 | 0 |
Twelve-lead ECG was performed after 5 minutes of rest in the supine position.
| Participants | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Open-label Extension Period: Number of Participants With Clinically Significant Changes in ECG | 0 | 0 | 0 |
Serum samples were collected for the analysis of total immunoglobulin G. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.
| Percent change | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Double-blind Treatment Period: Percent Change From Baseline in Levels of Total Immunoglobulin G (IgG) | -3.17 ± 2.97 | -59.49 ± 3.15 | -77.66 ± 2.92 |
Serum samples were collected for the analysis of IgG 1, 2, 3 and 4 levels. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.
| Percent change | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| IgG1 | -3.3 ± 3.67 | -65.9 ± 4.02 | -76.3 ± 3.98 |
| IgG2 | -2.2 ± 5.35 | -54.7 ± 5.65 | -63.6 ± 5.60 |
| IgG3 | -2.1 ± 4.69 | -68.2 ± 5.05 | -82.9 ± 5.12 |
| IgG4 | -3.1 ± 5.68 | -48.0 ± 6.08 | -64.7 ± 6.10 |
Serum samples were collected for the analysis of Anti-AChR-IgG. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.
| Percent change | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Double-Blind Treatment Period: Percent Change From Baseline in Anti-acetylcholine Receptor Immunoglobulin G (Anti-AChR-IgG) at Week 7 | 15.92 ± 12.41 | -46.66 ± 13.64 | -85.28 ± 12.27 |
Blood samples were collected for the analysis of Pharmacokinetic parameter AUC (0-168h).
| Hours*microgram per milliliter | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|
| Double-Blind Treatment Period: Area Under the Concentration-time Curve From Time 0 to 168 Hours (AUC0-168h) of RVT-1401 | NA ± NA | NA ± NA |
Pharmacokinetic parameters were not estimated because the sparse PK sampling schedule did not allow for accurate estimates of these parameters.
| Hours*microgram per milliliter | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|
| Open-label Extension Period: AUC0-168h of RVT-1401 | NA ± NA | NA ± NA |
Blood samples were collected for the analysis of Pharmacokinetic parameter Cmax.
| micrograms per milliliter | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|
| Double-Blind Treatment Period: Maximum Concentration (Cmax) of RVT-1401 | NA ± NA | NA ± NA |
Blood samples were collected for the analysis of Pharmacokinetic parameter Cmax.
| Micrograms per milliliter | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|
| Open-label Extension Period: Cmax of RVT-1401 | NA ± NA | NA ± NA |
Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic RVT-1401.
| Milligrams per liter | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|
| Double-Blind Treatment Period: Trough Concentrations (Ctrough) of RVT-1401 | NA ± NA | NA ± NA |
Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic RVT-1401.
| Milligrams per liter | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|
| Open-label Extension Period: Ctrough of RVT-1401 | NA ± NA | NA ± NA |
The QMG score is a physician-reported outcome measure was used to assess MG disease severity and pattern of deficits based on quantitative testing of affected muscle groups. The scale comprised of 13 test items that were graded on a scale of 0 (no myasthenic findings) to 3 (maximal myasthenic deficits). The total sum across all 13 items represents the QMG score. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Scores on a scale | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Week 2, n=6,5,6 | -3.3 ± 2.16 | -2.8 ± 5.36 | -1.7 ± 3.14 |
| Week 3, n=6,5,6 | -2.5 ± 2.74 | -4.6 ± 7.70 | -2.5 ± 2.95 |
| Week 4, n=6,5,5 | -2.7 ± 2.73 | -3.6 ± 6.43 | -3.6 ± 4.16 |
| Week 5, n=6,5,5 | -2.7 ± 2.73 | -3.2 ± 6.80 | -3.2 ± 3.70 |
| Week 6 (Day 36), n=6,5,5 | -3.0 ± 3.22 | -4.0 ± 6.75 | -4.4 ± 3.71 |
| Week 7, n=5,5,5 | -1.8 ± 3.27 | -4.0 ± 6.82 | -3.8 ± 4.76 |
The response is defined as improvement from Baseline on the QMG score by =\> 3 points. The QMG score is a physician-reported outcome measure was used to assess MG disease severity and pattern of deficits based on quantitative testing of affected muscle groups. The scale comprised of 13 test items that were graded on a scale of 0 (no myasthenic findings) to 3 (maximal myasthenic deficits). The total sum across all 13 items represents the QMG score. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Percentage of participants | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Double-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the QMG Score From Baseline | 20.0 | 40.0 | 60.0 |
The MG-ADL is an 8-item, participant-reported outcome measure that assessed Myasthenia Gravis symptoms and their effects on activities of daily living, with each response graded from 0 (normal) to 3 (most severe). The MG-ADL score was calculated by totaling the rating for each of the 8 items. Total MG-ADL scores range from 0 to 24 with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Scores on a scale | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Week 2 | -1.7 ± 2.34 | -3.2 ± 6.61 | -0.7 ± 0.82 |
| Week 3 | -0.8 ± 2.04 | -3.8 ± 5.97 | -1.7 ± 1.97 |
| Week 4 | -0.8 ± 2.64 | -3.2 ± 6.38 | -2.0 ± 2.35 |
| Week 5 | -1.5 ± 3.02 | -3.2 ± 6.65 | -2.0 ± 2.35 |
| Week 6 (Day 36) | -1.2 ± 3.19 | -5.2 ± 7.09 | -3.4 ± 3.36 |
| Week 7 | -0.2 ± 2.71 | -4.4 ± 7.06 | -3.2 ± 3.11 |
The response was defined as improvement (decrease) from Baseline on the MG-ADL score by =\> 2 points. The MG-ADL is an 8-item, participant-reported outcome measure that assessed Myasthenia Gravis symptoms and their effects on activities of daily living, with each response graded from 0 (normal) to 3 (most severe). The MG-ADL score was calculated by totaling the rating for each of the 8 items. Total MG-ADL scores range from 0 to 24 with higher scores indicating more severe disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug.
| Percentage of participants | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Double-Blind Treatment Period: Percentage of Participants With an Improvement/ Response on the MG-ADL Score | 33.3 | 60.0 | 60.0 |
The MGC was developed by selecting the best performing items from 3 commonly used Myasthenia Gravis specific scales (QMG, Myasthenia Gravis manual muscle test, and MG-ADL) and is comprised of 10 functional domains: 3 ocular, 3 bulbar, 1 respiratory, 1 neck, and 2 limb items. The total score ranges from 0 (no myasthenic findings) to 50 (maximal myasthenic deficits). The scale measures symptoms and signs of MG in these domains incorporating both physician and participant-reported test items. Higher scores correlate with clinical worsening of the disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Scores on a scale | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Week 2 | -2.3 ± 2.94 | -7.0 ± 9.27 | -3.0 ± 3.10 |
| Week 3 | -1.3 ± 5.20 | -8.8 ± 9.98 | -2.3 ± 2.88 |
| Week 4 | -2.0 ± 8.10 | -7.2 ± 10.40 | -4.0 ± 6.60 |
| Week 5 | -4.3 ± 7.50 | -7.0 ± 10.07 | -2.8 ± 4.97 |
| Week 6 (Day 36) | -2.5 ± 8.04 | -10.4 ± 9.32 | -6.6 ± 5.13 |
| Week 7 | -0.8 ± 7.33 | -9.0 ± 10.12 | -7.0 ± 5.34 |
The response was defined as improvement (decrease) from Baseline on the MGC score by =\> 3 points. The MGC was developed by selecting the best performing items from 3 commonly used Myasthenia Gravis specific scales (QMG, Myasthenia Gravis manual muscle test, and MG-ADL) and is comprised of 10 functional domains: 3 ocular, 3 bulbar, 1 respiratory, 1 neck, and 2 limb items. The total score ranges from 0 (no myasthenic findings) to 50 (maximal myasthenic deficits). The scale measures symptoms and signs of MG in these domains incorporating both physician and participant-reported test items. Higher scores correlate with clinical worsening of the disease. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug.
| Percentage of participants | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Double-Blind Treatment Period: Percentage of Participants With an Improvement on the MGC Score | 40.0 | 60.0 | 60.0 |
The MG-QOL15r is a participant-reported questionnaire designed to assess how a participant's Myasthenia Gravis affects different aspects related to their quality of life. The scale includes 15 items that are graded on a scale of 0 to2; the total across is the sum of all 15 items and represents the MG-QOL15r score. The range of the MG-QOL15r score is 0 - 30. Higher scores indicate worse outcomes. Baseline was defined as the last non-missing value prior to the date (time) of first dose of study drug. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Scores on a scale | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Week 4 | -3.5 ± 3.83 | -6.0 ± 9.77 | 1.6 ± 5.03 |
| Week 7 | -2.3 ± 3.93 | -6.6 ± 10.55 | 2.0 ± 4.42 |
The serum levels of anti-RVT-1401 antibodies were determined. All samples that were potentially positive were analyzed with the confirmation assay where presence of anti-RVT-1401 was confirmed; the therapeutic antibody was used to compete with the analytical responses of anti-drug antibody (ADA) to assess specificity of screened positive samples.
| Participants | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Double-Blind Treatment Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies | 2 | 1 | 1 |
The serum levels of anti-RVT-1401 antibodies were determined. All samples that were potentially positive were analyzed with the confirmation assay where presence of anti-RVT-1401 was confirmed; the therapeutic antibody was used to compete with the analytical responses of ADA to assess specificity of screened positive samples.
| Participants | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week |
|---|---|---|---|
| Open-Label Extension Period: Number of Participants Reporting Confirmed Positive Anti-RVT-1401 Antibodies | 1 | 0 | 0 |
Collected over From Baseline and Up to Week 18. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Treatment Period: Placebo | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Double-blind Treatment Period: RVT-1401 340 mg/Week | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Double-blind Treatment Period: RVT-1401 680 mg/Week | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Open-label Extension Period: RVT-1401 340 mg Biweekly | 0/15 (0%) | 1/15 (6.7%) | 10/15 (66.7%) |
| Event | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week | Open-label Extension Period: RVT-1401 340 mg Biweekly |
|---|---|---|---|---|
| Herpes simplexInfections and infestations | 0/6 | 0/5 | 1/6 | 0/15 |
| Myasthenia gravisNervous system disorders | 0/6 | 0/5 | 0/6 | 1/15 |
| Event | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week | Open-label Extension Period: RVT-1401 340 mg Biweekly |
|---|---|---|---|---|
| HeadacheNervous system disorders | 3/6 | 1/5 | 0/6 | 2/15 |
| Injection site erythemaGeneral disorders | 1/6 | 2/5 | 1/6 | 2/15 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/6 | 1/5 | 0/6 | 1/15 |
| DizzinessNervous system disorders | 1/6 | 0/5 | 2/6 | 0/15 |
| Injection site bruisingGeneral disorders | 0/6 | 1/5 | 0/6 | 0/15 |
| Injection site swellingGeneral disorders | 1/6 | 1/5 | 0/6 | 1/15 |
| Upper respiratory tract infectionInfections and infestations | 0/6 | 1/5 | 0/6 | 0/15 |
| Urinary tract infectionInfections and infestations | 0/6 | 1/5 | 0/6 | 0/15 |
| Red blood cell count increasedInvestigations | 0/6 | 1/5 | 0/6 | 0/15 |
| White blood cells urine positiveInvestigations | 0/6 | 1/5 | 0/6 | 0/15 |
Safety Analysis Set (SAF) comprised of all participants who received at least 1 dose of study medication.
| Age, Continuous(Years) | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week | Total |
|---|---|---|---|---|
| Mean | 41.0 ± 15.40 | 56.8 ± 22.17 | 70.8 ± 14.22 | 56.2 ± 20.67 |
| Sex: Female, Male(Participants) | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week | Total |
|---|---|---|---|---|
| Female | 4 | 2 | 1 | 7 |
| Male | 2 | 3 | 5 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 5 | 5 | 16 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Double-blind Treatment Period: Placebo | Double-blind Treatment Period: RVT-1401 340 mg/Week | Double-blind Treatment Period: RVT-1401 680 mg/Week | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 6 | 5 | 6 | 17 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in Oct 2020, 16 months.
Results were first posted in Dec 2023, 3 years 2 months after primary completion. A results delay was requested in Oct 2021.
Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HBM9161
Immunovant Sciences GmbH